文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

罗沙司他与安慰剂治疗较低危骨髓增生异常综合征患者:MATTERHORN 3期双盲随机对照试验

Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial.
PubMed 文献 · Am J Hematol · 2024-06-17

MATTERHORN 3期双盲随机对照试验评估口服罗沙司他(2.5 mg/kg,每周三次)与安慰剂治疗输血依赖的较低危骨髓增生异常综合征/肿瘤(MDS)患者,因中期分析未达统计学显著性而终止。最终分析中罗沙司他组输血独立应答者38/80(47.5%),安慰剂组19/57(33.3%),p=0.217。在每4周输血负荷≥2单位pRBC的患者中,罗沙司他组应答率36.1%(13/36)高于安慰剂组11.5%(3/26),名义p=0.047。

要点

  • 罗沙司他组输血独立应答率47.5%(38/80) vs 安慰剂组33.3%(19/57),p=0.217,未达统计学显著。
  • 每4周输血负荷≥2单位pRBC患者中,罗沙司他组应答率36.1%(13/36) vs 安慰剂组11.5%(3/26),名义p=0.047。
  • 试验因中期分析结果未达统计学显著性而终止;需进一步分析确认可从该新治疗获益的MDS患者亚组。

核心结论

  • 尽管MATTERHORN未达到主要终点,罗沙司他治疗相比安慰剂获得数值上更高的输血独立率。
  • 需进一步分析以确认可从该新治疗获得临床获益的MDS患者亚组。

研究设计与样本

  • MATTERHORN为随机、双盲、3期试验,评估罗沙司他与安慰剂治疗输血依赖的较低危MDS患者。
  • 纳入极低危、低危或中危MDS患者,不论既往是否接受促红细胞生成素刺激剂治疗,输血负荷为每8周1-4单位浓缩红细胞(pRBC)。
  • 患者按3:2随机接受口服罗沙司他(2.5 mg/kg)或安慰剂,均每周三次,联合最佳支持治疗。
  • 主要疗效终点为28周内输血独立(TI)持续≥56天(TI应答者)。
  • 共筛查272例患者,入组140例(罗沙司他组82例,安慰剂组58例)。

主要发现

  • 最终分析中,罗沙司他组38/80(47.5%)与安慰剂组19/57(33.3%)为TI应答者(p=0.217)。
  • 在每4周输血负荷≥2单位pRBC的患者中,罗沙司他组TI应答率为36.1%(13/36),安慰剂组为11.5%(3/26)(名义p=0.047)。
  • 研究期间共7例死亡(罗沙司他组4例,安慰剂组3例),均被认为与治疗无关。
  • 3例罗沙司他组患者进展为急性髓系白血病。

局限性

  • MATTERHORN因中期分析结果未达统计学显著性而终止。
  • 需进一步分析以确认可从该新治疗获得临床获益的MDS患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In patients with lower-risk myelodysplastic syndromes/neoplasms (MDS), response to first-line therapy is limited and transient. The MATTERHORN randomized, double-blind, phase 3 trial evaluated roxadustat versus placebo for patients with transfusion-dependent, lower-risk MDS. Eligible patients had very low-, low-, or intermediate-risk MDS with or without prior erythropoiesis-stimulating agent treatment, and a transfusion burden of 1-4 packed red blood cell (pRBC) units every 8 weeks (Q8W). Patients were randomized (3:2) to oral roxadustat (2.5 mg/kg) or placebo, both three times weekly, with best supportive care. Primary efficacy endpoint was transfusion independence (TI) for ≥56 days within 28 weeks (TI responders). MATTERHORN was terminated due to interim analysis outcomes not meeting statistical significance. In total, 272 patients were screened, and 140 patients were enrolled (82, roxadustat, and 58, placebo). At final analysis, 38/80 (47.5%) patients and 19/57 (33.3%) in the roxadustat and placebo arms, respectively, were TI responders (p = .217). A greater percentage of patients in the roxadustat arm with a transfusion burden of ≥2 pRBC units Q4W were TI responders (36.1%; 13/36) compared with the placebo arm (11.5%; 3/26; p-nominal = .047). The seven on-study deaths (4, roxadustat, and 3, placebo) were considered unrelated to treatment. Three roxadustat patients progressed to acute myeloid leukemia. Despite MATTERHORN not meeting its primary endpoint, a numerically higher TI rate was achieved with roxadustat treatment compared with placebo. Further analyses are needed to confirm the MDS patient subgroups deriving clinical benefit from this novel treatment.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Mittelman M, Henry DH, Glaspy JA, et al. Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematol. 2024. PMID: 38884137. doi:10.1002/ajh.27410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。